SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10794	Companies
233227	Keywords
161807	Articles
124404	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 02/24/2026 at 15:30, 5 months 6 days ago

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
Dupixent de Sanofi et Regeneron approuvé par la FDA aux États-Unis pour traiter la rhinosinusite fongique allergique, offrant un soulagement aux patients de tous âges

Traitement Sanofi Dupixent Regeneron Rhinosinusite Fongique Allergique
PRESS RELEASE

published on 02/24/2026 at 15:30, 5 months 6 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease

Sanofi Phase 3 Study Dupixent Regeneron Allergic Fungal Rhinosinusitis
BRIEF

published on 02/17/2026 at 19:05, 5 months 13 days ago

Sanofi publie son Document d'Enregistrement Universel 2025

Rapport Financier SEC Durabilité Sanofi Document D'enregistrement
BRIEF

published on 02/17/2026 at 19:05, 5 months 13 days ago

Sanofi publishes its 2025 Universal Registration Document

Sustainability Financial Report Sanofi Registration Document DRY
PRESS RELEASE

published on 02/17/2026 at 19:00, 5 months 13 days ago

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
Dépôt du Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel et du « Form 20-F » américain par Sanofi. Consultation en ligne disponible

Rapport Financier Annuel Form 20-F Document D’enregistrement Universel Sanofi Consultation En Ligne
BRIEF

published on 02/17/2026 at 12:05, 5 months 13 days ago

Sanofi and Teva: Promising advance in the treatment of inflammatory bowel diseases

Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
BRIEF

published on 02/17/2026 at 12:05, 5 months 13 days ago

Sanofi et Teva annoncent des résultats positifs de phase 2b pour Duvakitug dans les MICI

Maladie De Crohn Rectocolite Hémorragique Étude De Phase 2b Duvakitug Collaboration Sanofi-Teva
BRIEF

published on 02/17/2026 at 12:05, 5 months 13 days ago

Sanofi et Teva : Avancée prometteuse dans le traitement des maladies inflammatoires intestinales

Maladie De Crohn Sanofi Colite Ulcéreuse Teva Duvakitug
BRIEF

published on 02/17/2026 at 12:05, 5 months 13 days ago

Sanofi and Teva Report Positive Phase 2b Data for Duvakitug in IBD

Ulcerative Colitis Crohn’s Disease Phase 2b Study Duvakitug Sanofi-Teva Collaboration
PRESS RELEASE

published on 02/17/2026 at 12:00, 5 months 13 days ago

Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn
Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva montrent une efficacité durable dans la colite ulcéreuse et la maladie de Crohn, renforçant le potentiel du traitement

Maladie De Crohn Sanofi Colite Ulcéreuse Teva Duvakitug

Accesswire

Published on 08/01/2026 at 01:58, 2 days 5 hours ago

Clôture de l'option sur la propriété de graphite au Québec
Published on 08/01/2026 at 01:20, 2 days 6 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 6 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 7 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 7 hours ago

BioNxt Solutions Announces Option Grants

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 07:30, 26 minutes ago

2CRSi SA: Mission d’investigation indépendante en lien avec les allégations du rapport Grizzly Research : 2CRSi précise le périmètre et le calendrier
Published on 08/03/2026 at 07:30, 26 minutes ago

2CRSi SA: Independent investigation into the allegations made in the Grizzly Research report: 2CRSi sets out the scope and timetable
Published on 08/03/2026 at 07:30, 26 minutes ago

q.beyond acquires majority stake in SAP healthcare specialist GITG
Published on 08/03/2026 at 07:30, 26 minutes ago

Nordex Group obtains 77 MW order in Romania
Published on 08/03/2026 at 07:29, 26 minutes ago

Deutsche Rohstoff AG: Share Buyback Program completed ahead of schedule

Les Echos

Published on 08/03/2026 at 07:00, 56 minutes ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 08/03/2026 at 07:00, 56 minutes ago

Biophytis fait un point d’étape et partage les perspectives de sa co-entreprise à Hong Kong
Published on 07/31/2026 at 21:00, 2 days 10 hours ago

Carrefour finalise la vente de sa participation minoritaire dans CarrefourSA en Turquie à Yeni Mağazacılık A.Ş., société opérant l'enseigne de A101 et contrôlée par le Groupe Aydın
Published on 07/31/2026 at 21:00, 2 days 10 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 12 hours ago

Share retention commitments (Dutreil Agreement)

View all LES ECHOS COMFI WIRE